Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Silo Pharma Inc
(OP:
SILO
)
N/A
UNCHANGED
Last Price
Updated: 3:23 PM EDT, Sep 14, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
-
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.1700
Today's Range
N/A - N/A
52wk Range
N/A - N/A
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
San Francisco Passes Resolution to Decriminalize Psilocybin Mushrooms
September 16, 2022
Via
Investor Brand Network
This Psychedelics Company Is Undertaking A 1:50 Reverse Stock Split To Enter NASDAQ
September 15, 2022
The psychedelics landscape changes quickly. Whether large or small, every biotech company is looking for ways to further advance their research and product & services commercialization.
Via
Benzinga
Performance
More News
Read More
Study Finds Depression Symptoms in Partners Caring for Dementia Patients May Start Long Before Cognitive Decline
September 14, 2022
Via
Investor Brand Network
Georgia Legislators Discuss Psychedelics for Veterans During Committee Hearing
September 13, 2022
Via
Investor Brand Network
New Research Finds Link Between Psychedelic-Induced Mystical Experiences and EcoFriendly Behavior
September 08, 2022
Via
Investor Brand Network
Silo Pharma Inc. (SILO): Promising Psylocibin Study Ongoing with UCSF
August 17, 2022
Via
Investor Brand Network
Research Indicates Better Sleep Efficiency Benefits Fibromyalgia Sufferers
September 06, 2022
Via
Investor Brand Network
Important Factors to Consider When Designing Psychedelic Clinical Trial Protocols
September 02, 2022
Via
Investor Brand Network
Psychedelics Company Raises More than $10M in Seed Funding to Advance Ketamine Therapy
August 30, 2022
Via
Investor Brand Network
Study Explains How Threatening Cues Are Refined into Fear Signals
August 26, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) Fusing Traditional Therapeutics with Psychedelic Research
August 25, 2022
Via
Investor Brand Network
Study Finds More Than 5.5 Million Adults in the US Use Hallucinogens
August 25, 2022
Via
Investor Brand Network
California Senator Sees New Path to Get Psychedelics Decriminalization Bill Approved
August 23, 2022
Via
Investor Brand Network
Study Finds Vitamin D May Help Alleviate Depression Symptoms
August 18, 2022
Via
Investor Brand Network
Psychedelics Advocates Put DEA Under Pressure Over Right to Try Laws
August 17, 2022
Via
Investor Brand Network
Second Psychedelics Initiative Fails to Qualify for Colorado Ballot
August 15, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc.’s (SILO) Ketamine Study Generates ‘Extremely Promising’ Data
August 12, 2022
Via
Investor Brand Network
Study Finds Smells Experienced in Nature Boost Mental Health
August 11, 2022
Via
Investor Brand Network
Leading Neuroscientist Explains How Psychedelics Alters the Brain
August 10, 2022
Via
Investor Brand Network
BioMedNewsBreaks – Silo Pharma Inc. (SILO) Reports Positive Results from Research on Novel Liposomes
August 04, 2022
Via
Investor Brand Network
Three Clinical Trials On Psychedelic Microdosing Worth Following
August 04, 2022
Via
Investor Brand Network
Silo Pharma Inc.’s (SILO) Ketamine Study Produces Positive Endpoint Results, Suggests Topical Formulation Reduces Neuropathic Nerve Pain
August 03, 2022
Via
Investor Brand Network
Research Finds That Tourism, Travel May Boost Mental Health
August 03, 2022
Via
Investor Brand Network
The DEA Rescinds Proposal to Ban Five Psychedelics
August 01, 2022
Via
Investor Brand Network
Preclinical Ketamine Trial Shows Positive Results For Pain Conditions Like Fibromyalgia And Arthritis
July 27, 2022
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
